Please ensure Javascript is enabled for purposes of website accessibility

Why Seelos Therapeutics Dived by 24% Today

By Eric Volkman - May 17, 2021 at 6:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Good news from a clinical study was overshadowed by a recommendation downgrade from an analyst.

What happened

The stock of Seelos Therapeutics (SEEL 4.52%), a clinical-stage biotech that focuses on central nervous system (CNS) afflictions, was hit with an over 24% sell-off on Monday. Seemingly positive clinical trial news was heavily tempered by an analyst downgrade.

So what

An open-label study of Seelos' SLS-002 drug aimed at treating acute suicidal ideation and behavior in patients suffering from major depressive disorder produced very promising results.

The company found that SLS-002 had a 76.5% response rate in its primary endpoint of notably reducing their baseline on the Montgomery-Asberg Depression Rating Scale (MADRS). That response rate was just under 93% for the secondary endpoint, which was a more modest MADRS reduction.

A medical professional using a microscope.

Image source: Getty Images.

In a press release, the biotech quoted its CEO Raj Mehra as saying this could mean that "SLS-002 [is] an ideal therapy for this large unmet need of acute suicidality in major depression."

Nevertheless, Roth Capital analyst Jonathan Aschoff downgraded both the target price and his recommendation on Seelos stock. The former is now $4 per share, from a previous $12, and for him the stock is now a neutral (formerly a buy). Aschoff feels that while the trial results are positive, he's concerned about SLS-002's performance in the study according to another scale that measures dissociation.

Now what

It should be stressed that this is an early-stage study (it involved only 17 participants), so more testing is required for SLS-002. Despite Aschoff's reservations these results are quite promising, but the more important research work is forthcoming.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Seelos Therapeutics, Inc. Stock Quote
Seelos Therapeutics, Inc.
SEEL
$0.93 (4.52%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.